valve

La angina microvascular podría tener gradientes de riesgo

Aligning Prosthetic Valves to Native Commissures: The Secret to Coronary Artery Obstruction?

Preventing coronary artery obstruction during transcatheter aortic valve replacement (TAVR) continues to be a challenge. There are techniques to prevent (or at least reduce) this from happening, which could be catastrophic. However, they all somehow fall into palliative care, that is, they will merely provide relief, rather than a cure.&nbsp; Commissure overlapping and the resulting<a href="https://solaci.org/en/2020/05/26/aligning-prosthetic-valves-to-native-commissures-the-secret-to-coronary-artery-obstruction/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

In Search of the Optimal Depth for Self-Expandable Valves

Despite the use of the different imaging approaches to calculating implantation depth, optimal depth is reached only 30% of the time. Multiple imaging does not offer a uniform perspective and therefore influence reporting.&nbsp; Basically, we do not have a clear idea of what constitutes optimal depth on a case by case basis and, what is<a href="https://solaci.org/en/2020/05/20/in-search-of-the-optimal-depth-for-self-expandable-valves/" title="Read more" >...</a>

implante de la valvula aortica transcateter

TAVR Reaches Low-Risk Patients with Bicuspid Valves

Transcatheter aortic valve replacement (TAVR) seems to be safe in low-risk patients with bicuspid aortic valve stenosis. Their hospital length of stay was very short, with zero mortality, and zero disabling stroke. Subclinical leaflet thrombosis and device durability are still unknown. The United States Food and Drug Administration (FDA) approved TAVR for low-risk patients. However,<a href="https://solaci.org/en/2020/04/27/tavr-reaches-low-risk-patients-with-bicuspid-valves/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Promising Outcomes of Transcatheter Mitral Valve Replacement in Complex Patients

Courtesy of Dr. Carlos Fava. The risk of repeat surgical mitral valve repair involves 6% to15% mortality at 30 days, even close to 20% in acute cases. However, mortality can rise to over 40% when it comes to a third or fourth surgical intervention.&nbsp; One of the solutions to this serious problem is transcatheter mitral<a href="https://solaci.org/en/2020/04/16/promising-outcomes-of-transcatheter-mitral-valve-replacement-in-complex-patients/" title="Read more" >...</a>

marcapasos tavi

Tricuspid valve: Is Percutaneous Intervention Feasible in Patients with Definite Pacemaker?

Courtesy of Dr. Carlos Fava. As we know, with higher life expectancy comes a significant increase in the use of definite pacemakers, defibrillators and resynchronization devices. Along these lines, the presence of catheters is associated to tricuspid regurgitation, which over time might become severe, leading to cardiac regurgitation and potentially heart failure.&nbsp; This group is<a href="https://solaci.org/en/2020/04/13/tricuspid-valve-is-percutaneous-intervention-feasible-in-patients-with-definite-pacemaker/" title="Read more" >...</a>

Mejoras tecnológicas en las válvulas que se traducen en resultados clínicos

Technological Improvements in Valves Translate into Clinical Results

Three generations of self-expanding valves, three different prognoses for our patients. Design improvements and better materials in self-expanding, supra-annular aortic valves, and their better results, have allowed for the expansion of the indication for transcatheter aortic valve replacement (TAVR). Particularly, the addition of a pericardial skirt improves annular sealing and results in a significantly low<a href="https://solaci.org/en/2020/04/08/technological-improvements-in-valves-translate-into-clinical-results/" title="Read more" >...</a>

Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves

The initial results of this study presented “virtually” at the American College of Cardiology (ACC) 2020 Scientific Session suggest that patients with severe bicuspid aortic stenosis can be treated with self-expandable valve Evolut. This is a small study presenting its 30-day outcomes. There is still a long way to go. The rate of all-cause mortality<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-first-results-of-evolut-in-low-risk-bicuspid-valves/" title="Read more" >...</a>

ACC Virtual 2020 | A diferencia del TAVI, el volumen de cirugías mitrales no mejora la reparación por catéter

Virtual ACC 2020 | Unlike in TAVR, the Number of Mitral Valve Surgeries Does Not Improve the Outcomes of Transcatheter Mitral Valve Repairs

Soon, our website will feature an interesting study showing that sites with a higher number of conventional surgical aortic valve replacements had better outcomes in transcatheter aortic valve replacement procedures. The study featured in this article was scheduled for presentation at the American College of Cardiology 2020 Scientific Session along the World Congress of Cardiology.<a href="https://solaci.org/en/2020/03/25/virtual-acc-2020-unlike-in-tavr-the-number-of-mitral-valve-surgeries-does-not-improve-the-outcomes-of-transcatheter-mitral-valve-repairs/" title="Read more" >...</a>

tavi calcificación del anillo mitral

TAVR in Small Annuli: Is There a Better Valve?

Transcatheter aortic valve replacement with the self-expandable valves has shown optimal clinical and electrocardiographic results in patients with small annuli. These supra-annular prosthetic valves seem somewhat better than the intra-annular balloon expandable.&nbsp; TAVR in general has better functional results in terms of patient/prosthesis mismatch. This seems especially true for patients with a small annulus.&nbsp; The<a href="https://solaci.org/en/2020/03/20/tavr-in-small-annuli-is-there-a-better-valve/" title="Read more" >...</a>

Estenosis aórtica moderada y disfunción ventricular ¿debería apurarse la indicación del recambio?

Treating Both Atrial Valves Improves Survival

Courtesy of Dr. Carlos Fava. There a few treatment options for tricuspid valve disease. It is practically limited to diuretics and surgery, is associated to high mortality and, generally, mitral regurgitation.&nbsp; Developing the “edge-to-edge” strategy with MitraClip has been shown beneficial and, at present, there are studies that claim this technique could be greatly beneficial<a href="https://solaci.org/en/2020/03/10/treating-both-atrial-valves-improves-survival/" title="Read more" >...</a>

Top